| " Strong versus weak prior for predicting patient recruitment at the start of clinical trials in the context of drug availability issues C Laloux, C Legrand, M Munda | | |
| 465 Cure Models in Cancer Clinical Trials C Legrand, A Bertrand i Textbook of Clinical Trials in Oncology: A Statistical Perspective, 465-492, 2019 | | 2019 |
| 5CHAPTER A Price, CL Legrand, S Dusenne, HGM Bartelink, G Giaccone, ... Radiotherapy and Cisplatin: outcome of combined modality treatment in non …, 2007 | | 2007 |
| A Bayesian approach to jointly estimate centre and treatment by centre heterogeneity in a proportional hazards model C Legrand, V Ducrocq, P Janssen, R Sylvester, L Duchateau Statistics in Medicine 24 (24), 3789-3804, 2005 | 50 | 2005 |
| A Bayesian approach to jointly estimate centre and treatment by centre heterogeneity in a proportional hazards model. Stat. Med C Legrand Open Access publications from Université catholique de Louvain, 2005 | | 2005 |
| A Bayesian framework for the ratio of two Poisson rates in the context of vaccine efficacy trials∗ S Laurent, C Legrand ESAIM: Probability and Statistics 16, 375-398, 2012 | 11 | 2012 |
| A copula-based simulation method for clustered multi-state survival data F Rotolo, C Legrand, I Van Keilegom, M Chiogna | | 2011 |
| A diagnostic plot for guiding the choice of the frailty distribution in clustered survival data M Munda, C Legrand Discuss. Pap 37, 2013 | 1 | 2013 |
| A general class of time-varying coefficients models for right censored data C Legrand, M Munda, P Janssen, L Duchateau LIDAM Discussion Papers ISBA, 2012 | | 2012 |
| A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons E Cantagallo, M De Backer, M Kicinski, B Ozenne, L Collette, C Legrand, ... Biometrical Journal 63 (2), 272-288, 2021 | 6 | 2021 |
| A note on tests for relevant differences with extremely large sample sizes A Callegaro, C Ndour, E Aris, C Legrand Biometrical Journal 61 (1), 162-165, 2019 | 5 | 2019 |
| A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956) GV Scagliotti, E Smit, L Bosquee, M O’Brien, A Ardizzoni, P Zatloukal, ... Lung cancer 50 (1), 91-96, 2005 | 44 | 2005 |
| A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956) C Legrand Open Access publications from Université catholique de Louvain, 2005 | | 2005 |
| A prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials J Francart, E Vaes, S Henrard, C Legrand, P Baas, R Gaafar, ... European journal of cancer 45 (13), 2304-2311, 2009 | 46 | 2009 |
| A prospective randomized study comparing the efficacy of Timentin alone or in combination with amikacin in the treatment of febrile neutropenic patients JP Bru, M Michallet, C Legrand, P Swierz, JP Stahl, JB Leautet, JJ Sotto, ... Journal of Antimicrobial Chemotherapy 17 (suppl_C), 203-209, 1986 | 18 | 1986 |
| A randomized phase II study comparing two schedules of the 21-day regime of Gemcitabine and Carboplatin in advanced NSCLC V Surmont, J Aerts, RJ Van Klaveren, K Tournoy, K Tan, RM Vernhout, ... | | 2009 |
| A randomized phase II study comparing two schedules of the 21-day regimen of gemcitabine and carboplatin in advanced non-small cell lung cancer V Surmont, J Aerts, RJ Van Klaveren, K Tournoy, KY Tan, RM Vernhout, ... Oncology 78 (3-4), 267-270, 2010 | 3 | 2010 |
| A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer … JP Van Meerbeeck, C Manegold, R Gaafar, RJ Van Klaveren, ... Journal of Clinical Oncology 22 (14_suppl), 7021-7021, 2004 | 31 | 2004 |
| A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma CA Camargo Jr, DM Gurner, HA Smithline, R Chapela, LM Fabbri, ... Journal of Allergy and Clinical Immunology 125 (2), 374-380, 2010 | 89 | 2010 |
| A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction … JP Van Meerbeeck, G Kramer, PE Van Schil, C Legrand, EF Smit, ... Journal of Clinical Oncology 23 (16_suppl), LBA7015-LBA7015, 2005 | 63 | 2005 |
